ENCOrafenib With Binimetinib in bRAF NSCLC
NCT04526782
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
119
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
BRAF V600E
Interventions
DRUG:
Encorafenib 75 MG
DRUG:
Binimetinib 15 MG
Sponsor
Intergroupe Francophone de Cancerologie Thoracique